MiMedx Group (MDXG): Price to Sales

Corporate company logo of MiMedx Group (MDXG)

MiMedx Group, Inc. (MDXG) tissue regeneration innovations are creating a capital burden, which confirms the historical P/S trend. The current level of 1.50 captures fresh market demand values. Cost optimization is based on in-house manufacturing plants and the moderate use of CROs. Revenue stability is ensured by the integration of products into surgical protocols, despite regulatory risks from the FDA.

MiMedx - MDXG P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for MiMedx Group (MDXG)

- current price and projected stock value:
Price Chart mimedx.com|MDXG - Price Target Chart
- stock exchange capitalization data:
Market Value MiMedx Group|MDXG - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share MiMedx|MDXG - Book Capitalization|Market Capitalization to Book Value mimedx.com|MDXG - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient MiMedx Group, Inc.|MDXG - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio MiMedx Corp|MDXG - Company Debts|Debt to Book Value MiMedx Group|MDXG - Company Long-Term Debts|Short-Term Debt Volume MiMedx|Quick Liquidity Indicator mimedx.com
- financial results and valuation multiples details:
MDXG - Net Profit|Expected Net Profit MiMedx Group, Inc.|MDXG - P/E Multiple|Price to Future Earnings Ratio MiMedx Group Inc|MDXG - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation MiMedx Group|MDXG - Operating profit before deduction of amortization|Earnings per share for the trailing year MiMedx|MDXG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year mimedx.com|MDXG - Earnings per share growth in current year|Expected earnings per share trend next year MiMedx Group, Inc.
- issuer revenue and sales details:
MDXG - Company Revenue|Company Expected Sales Volume mimedx.com|MDXG - Market Cap to Revenue|Forward P/S Multiple MiMedx Group
Fundamental company analysis:MDXG (mimedx.com)
Core merchandise of MiMedx Group, Inc.

For MiMedx Group, Inc. (MDXG), high profitability of bio-implants and operating leverage during scaling make the price-to-sales multiple a key indicator of expansion efficiency. This metric determines the value of a single dollar of revenue, allowing for an assessment of whether the market is overvaluing current sales relative to profit growth potential and the risks of asset undervaluation.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Price-to-Revenue Ratio 89bio, Inc. ETNB|AGIO - Market Cap to Revenue|Structure Therapeutics Inc. - P/S Multiple|Price-to-Revenue Coefficient Rezolute Inc RZLT|Lexicon Pharma (LXRX) - Price-to-Revenue Ratio|Market Cap to Revenue MBX Corp|ALT (Altimmune, Inc.) - P/S Multiple|Price to Sales aardvarktherapeutics.com AARD|P/S Multiple SGMT|BioAge Labs - Market Cap to Revenue Ratio|Biomea - Market Cap to Revenue|QNCX: Market Cap to Revenue Ratio|GUTS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VTVT (vTv Therapeutics Inc.)|ATPC: P/S Multiple|Price-to-Revenue Multiple Pluri PLUR|Price-to-Revenue Ratio Synlogic Inc.|LPCN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Matinas BioPharma (MTNB)|SPRB - Price to Sales|Galecto - Market Cap to Revenue|P/S Multiple Carmell Corp. CTCX|LUMO - Price-to-Revenue Ratio|Price-to-Sales Ratio ONVO|RDUS (Radius Recycling, Inc.) - Market Cap to Revenue